Seven analysts set USD 6.23 target for Ironwood Pharmaceuticals stock

Published on 10/15/2026 at 18:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter 2026 revenue reached USD 113.04 million, up 32.62 percent. Ironwood Pharmaceuticals stock costs EUR 3.40 on October 15, 2026.

Analyst target and quarterly scale

Seven analysts had a USD 6.23 average target on October 13, 2026.
GAAP net income reached USD 51.29 million in the second quarter of 2026 versus USD 23.60 million a year earlier.
Ironwood Pharmaceuticals stock traded at EUR 3.40 at Lang & Schwarz on October 15, 2026 at 6:33 p.m. CEST.
Market capitalization stood at USD 632.9 million on October 15, 2026.

IRWD, US46333X1081, Illustration mit AI erstellt.

Seven analysts had set a USD 6.23 average 12-month target for Ironwood Pharmaceuticals stock by October 13, 2026, according to MarketBeat. That target was 62.66 percent above the USD 3.83 Nasdaq quote available at 12:39 p.m. ET on October 15, 2026. The Nasdaq quote was up 6.39 percent from USD 3.60. Ironwood Pharmaceuticals was trading at EUR 3.40 at Lang & Schwarz on October 15, 2026 at 6:33 p.m. CEST.

Second-quarter figures set the scale

Ironwood reported second-quarter 2026 revenue of USD 113.04 million, compared with USD 85.24 million in the second quarter of 2025, a 32.62 percent increase. Ironwood Pharmaceuticals also reported GAAP net income of USD 51.29 million, versus USD 23.60 million a year earlier.

Adjusted EBITDA rose to USD 83.04 million from USD 50.10 million in the year-ago quarter. Operating cash flow reached USD 58.28 million in the second quarter of 2026, up from USD 15.10 million in the second quarter of 2025.

Stock remains below its yearly high

The Nasdaq quote stood at USD 3.83 on October 15, 2026 at 12:39 p.m. ET, within a 52-week range of USD 1.43 to USD 5.78. The price was 33.74 percent below the high and 167.83 percent above the low. Trading volume was 1,005,106 shares against an average of 1,982,048 shares.

Valuation and market comparison

Ironwood's market capitalization was USD 632.9 million on October 15, 2026, while its trailing P/E ratio was 5.00. The latest company results also showed USD 79.13 million in cash and cash equivalents as of June 30, 2026.

The October 15, 2026 comparison uses the same-day Nasdaq quote and company valuation figures.

Comparison with peers

IRWD: plus 6.39 percent, P/E 5.00, market capitalization USD 632.9 million
AbbVie (NYSE, USD): plus 2.42 percent, P/E 81.34, market capitalization USD 510.0 billion
Takeda Pharmaceutical (NYSE, USD): plus 3.87 percent, P/E 55.12, market capitalization USD 62.7 billion

Price for German-market investors

The euro quote was EUR 3.40 at Lang & Schwarz on October 15, 2026 at 6:33 p.m. CEST. On Nasdaq, the stock was trading at USD 3.83 at 12:39 p.m. ET on the same date.

The further course of trading is shown by the continuously updated real-time quote of Ironwood Pharmaceuticals stock.